Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Discrete Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

LetSync: Pilot Test of Mobile Health (mHealth) Intervention

NCT04951544
View directory record Official record
Conditions
HIV/AIDS
Interventions
LetSync app
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134
View directory record Official record
Conditions
HIV Infections
Interventions
TRIUMEQ, DOVATO
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

Family Treatment for Adolescents With Anorexia Nervosa

NCT01280799
View directory record Official record
Conditions
Anorexia Nervosa, Subthreshold Anorexia Nervosa, Eating Disorder Not Otherwise Specified, Primarily Restriction
Interventions
Acceptance-based separated family treatment
Behavioral
Lead sponsor
Towson University
Other
Eligibility
12 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Results available

Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

NCT00995904
View directory record Official record
Conditions
Asthma
Interventions
84ug MAP0020, 42ug MAP0020, 21ug MAP0020
Drug
Lead sponsor
Allergan
Industry
Eligibility
4 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 31, 2026, 1:44 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health

NCT05541887
View directory record Official record
Conditions
Cognitive Performance, Memory, Mood, Anxiety
Interventions
Muscadine Wine Polyphenol, Placebo
Other
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional

A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions

NCT04382521
View directory record Official record
Conditions
Hyperlipemia, Hypertension, Type2 Diabetes
Interventions
Text Message Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting No phase listed Observational

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619
View directory record Official record
Conditions
Melanoma
Interventions
Single agent, adjuvant anti-PD1 therapy
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional

Volumetric Analysis in Autologous Fat Grafting to the Foot

NCT02638532
View directory record Official record
Conditions
Pedal Fat Pad Atrophy
Interventions
Foot Fat Pad Grafting
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 31, 2026, 1:44 AM EDT
Terminated Phase 2Phase 3 Interventional

Bone Disease in Severely Burned Children

NCT00591162
View directory record Official record
Conditions
Burn
Interventions
Tetracycline, Duel Energy X-Ray Absorptiometry (DEXA), Bone Biopsy
Drug · Radiation · Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
5 Years to 18 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2008
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional Results available

Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia

NCT04309370
View directory record Official record
Conditions
Schizophrenia
Interventions
20 Hz rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 31, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional Results available

PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine

NCT00437203
View directory record Official record
Conditions
Neoplasms
Interventions
PF-00477736, gemcitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Santa Monica, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Poke and a Placebo

NCT04497220
View directory record Official record
Conditions
Anesthesia
Interventions
Negative Connotation Langauge, Positive Connotation Language
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional Results available

Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata

NCT00791908
View directory record Official record
Conditions
Cherry Angioma
Interventions
Electrodessication, Pulsed dye laser (PDL), potassium titanyl phosphate (KTP)
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional Results available

Actigraphic Analysis of Treatment Response

NCT00723580
View directory record Official record
Conditions
Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
Interventions
risperidone
Drug
Lead sponsor
Child Psychopharmacology Institute
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Combination Therapies for Gonorrhea Treatment

NCT00926796
View directory record Official record
Conditions
Gonorrhoea
Interventions
Azithromycin, Gentamicin, Gemifloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 60 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT03886662
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
LB-100
Drug
Lead sponsor
Lixte Biotechnology Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

NCT02877225
View directory record Official record
Conditions
Healthy
Interventions
Ibrutinib, IMBRUVICA
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Phase 1 Interventional

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BG-C9074, Tislelizumab, Bevacizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.

NCT00211770
View directory record Official record
Conditions
Autism
Interventions
Behavioral Assessment
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

NCT03222310
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ipatasertib, Itraconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 31, 2026, 1:44 AM EDT
Not yet recruiting Early Phase 1 Interventional

Individualized fMRI-guided TMS for Depression

NCT07804459
View directory record Official record
Conditions
Depression, Major Depressive Disorder (MDD), Depression - Major Depressive Disorder, Persistent Depressive Disorder, PDD, MDD
Interventions
Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed No phase listed Observational

Accuracy of Visual Range of Motion Estimates

NCT04038450
View directory record Official record
Conditions
Accuracy of Estimation of Joint Range of Motion
Interventions
No intervention
Other
Lead sponsor
Methodist University, North Carolina
Other
Eligibility
Not listed
Enrollment
522 participants
Timeline
2019
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 31, 2026, 1:44 AM EDT